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Abstract
Purpose: Fractionated radiation dose therapy is a routine procedure for the breastcancer treatment. However, despite of continuous improvement, tumor recurrenceoccurs in high proportion of the patients. There is a need of suitableradioresistance cell line system to study the properties of tumor recurrence. But,developing a radioresistant cancer cell line is a time requiring process. It requires amultiple radiation dosages for a period of three to four months. The present studyaims for the new strategy to develop a radioresistant breast cancer MCF-7 cell line.
Methods: The cells were exposed to 4Gy dosage of ϒ rays prior to 10Gy dose andsubjected for clonogenic assay. The cells survived in the clonogenic assay werepooled and named as RR-MCF-7. These cells were subjected to Bcl-2 analysis,apoptotic assay and LDH assay. Results: Developed cell line, RR-MCF-7 showedenhanced expression of Bcl-2 protein, which resulted in the declined apoptotic cellpercentage. Though there was destabilization in the membrane of the irradiatedcells, there was no significant difference observed in LDH level. Cloning efficiencyof the 10 Gy exposed cells was found to be more when it was given a 4 Gy of priordosage. The cells survived with this dosage showed the resistant character.
Conclusion: The approach followed in the current study for developingradioresistant cell line has reduced the time and dose requirement, also succeededin obtaining resistant characters in it.
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1. IntroductionFractionated radiation is used frequently in radiationtherapy treatment to aid the recovery of normal cells ortissues, while the repair of tumor cells is generally lesscompetent between fractions. However, the acquiredradioresistance of cancer cells is thought to occur duringthe re-growth of the tumor during the long-termfractionated radiation.1 Breast cancer derived tumorinitiating cells (TICs) are relatively resistant to ionizingradiation and chemotherapy. This could be a majordeterminant of tumor recurrence following treatment.2TICs are known for decreased amount of reactive oxygenspecies (ROS) production in monolayer culture compareto non TICs.3 A radio-resistant cell bypasses theradiation induced DNA double strand breaks (DSBs) byATM/DNA-PKcs dependent phosphorylation of histone
H2AX.4 Hyperphosphorylation of p53, RB and CHK2 arealso responsible for the resistance property in cancercells.5Generation of radioresistant cells for the studies is alaborious process. It requires almost five months todevelop radioresistant property in breast cancer cellMDA-MB 231.4 Gy Cobalt-60 dosage was used up to 13times to achieve total dosage of approximately 50 Gy.These cells showed the over expressions ofanti-apoptotic proteins such as Bcl-2, Bcl-XL, wereconsidered as the sign of radioresistance.6 The study byLi et al has used total of 80 Gy X-ray radiation with 4week interval after 10 Gy dosage on EC109 esophagealcancer cells. The study showed, there was lesser amount
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of apoptotic cells in radioresistant cells than controlgroup when it was exposed to 12 Gy X-ray radiation.7The present study focused on the new approach for thedevelopment of radio-resistant character in breastcancer cell line MCF-7.
2. Methods and Materials
2.1. Cell culture and maintenanceThe MCF-7 cancer cell line were purchased from NCCSPune, the cells were grown in MEM medium (Himedia)supplemented with 10% fetal bovine serum(FBS-Himedia) and maintained in a humidified 5% CO2atmosphere at 37°C.
2.2. Generation of radio-resistant characterMCF-7 cells (1×105) were plated in 25 cm3 culture flaskand at 60% confluence it was irradiated with 4 Gy ofϒ-rays using blood irradiated at, CAART center,Mangalore University. Immediately followingirradiation, the culture flask was renewed and cells werereturned to the incubator. When the MCF-7 cells reachedapproximately 90% confluence, they were trypsinized,counted and passaged into new flasks. Now the cellswere irradiated to 10 Gy and then it was subjected tocolonogenic assay. The cells were maintained intriplicate, two for the colony counting and one for thecell recovery. After two weeks the cells were pooledfrom the colony and observed for radioresistantcharacters and it was named as radioresistant MCF-7(RR-MCF-7).
2.3. Clonogenic assayPost 10 Gy exposure the cells were seeded on to 25 cm3flask for clonogenic assay. The flasks were incubated for2 weeks at 37oC in CO2 incubator. The colonies werefixed with pure ethanol and stained with 1% crystalviolet, washed and air-dried. Colonies consisting of 35 ormore cells were counted as clonogenic survivors. Thesurviving fraction (SF) was calculated by dividing thenumber of colonies by the number of cells seeded andthen multiplying by the plating efficiency.
2.4. Apoptotic assayMCF-7 and RR-MCF-7 cells were exposed to 4 Gy ofradiation and 24 hours after incubation cells weretrypsinized, pelleted by centrifuged at 1000 rpm for 5min and washed with 1 ml of PBS. The cell pellets werethen re-suspended in 25 µl of PBS and 2 µl of EB/AO dyemix. Stained cell suspension (10 µl) were placed on aclean glass slide and covered with a coverslip. Cells wereviewed under 40x of fluorescent microscope (Olympus).Minimum 200 cells were counted and percentages ofapoptotic cells were calculated.8
2.5. Membrane integrityLDH is a soluble cytosolic enzyme present in mosteukaryotic cells, released into culture medium upon celldeath due to damage of plasma membrane. The increaseof the LDH activity in culture supernatant isproportional to the number of lysed cells. LDH test wasused to assess the cell membrane integrity.9 Hundredmicrolitres of supernatant was taken out from each flaskfor LDH assay following the instruction of the kit(Agappe). The absorbance at 340 nm was recorded on aMicroplate Reader (Thermo scientific). The LDH leakageis expressed as U/L. The LDH level in the RR-MCF-7group was compared with other experimental groupssuch as control, 4 Gy and 10 Gy exposed MCF-7 cells.
2.6. Total Bcl-2 Sandwich ELISATotal Bcl-2 concentration in lysate of MCF-7 control celland RR-MCF-7 cells were measured using PathScan®Total Bcl-2 Sandwich ELISA Kit (#12030 Cell signalling).Standard protocols were followed as given in the kitmanual. The samples were read using microplate reader(Thermo scientific).
2.7. Western blottingWestern blottings using rabbit anti-human Bcl-2antibody (#138800 Molecular Probes) was performedaccording to standard protocols. Total proteins wereseparated using SDS-PAGE (Life Technology) and it wastransferred on to nitrocellulose membrane usingWestern blot instrument (iBolt-Life technology). HRPconjugated chromogenic detection was performed andimages were captured. Beta actin (AM4302-Invitrogen)was used as a marker protein for analysis. The bandintensity was measured using ImageJ software.
Figure 1: Comparison of clonogenic efficiency of 10 Gy and4 Gy + 10 Gy with control.
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Figure 2: Percentage of apoptosis in Radioresistance cellline (RR-MCF-7).
Figure 3:Membrane integrity: Concentration of leaked LDHin different irradiated samples
3. ResultsDosage of 4 Gy ϒ-radiation before 10 Gy exposurehelped to enhance the cloning efficiency of the cells.Cloning efficiency was decreased up to 8.2 percent in 10Gy exposed cell when compared to control (55.65%). Itwas comparatively increased up to 24.54% in 4 Gy+10Gy group (Figure 1). The cells named RR-MCF-7 showedsignificantly (P < 0.01) lower apoptotic cell percentagethan control group at 24 hr after 4 Gy exposure (Figure2). The irradiated cells have lost the membraneintegrity, which was measured by leaked LDH level inthe cultured media. There was no significant (P > 0.05)in LDH level among irradiated groups but it wascomparatively higher than control (98.35 ± 5.56) (Figure3).The reports of ELISA showed there was 2.43 folds higherBcl-2 protein in the RR-MCF-7 group than control. Thesurvived colonies in the clonogenic assay showed upto4.79 ± 0.56 ng/ml of Bcl-2 protein. The cells exposed to4 Gy and 10 Gy showed 2.99 ± 0.5, 2.45 ± 0.9 ng/ml ofBcl-2 protein (Figure 4). It was significantly (P < 0.05)less when compared to the RR-MCF-7 group. Similarresults observed in western blotting analysis. Theobtained band intensity was significantly (P < 0.05)higher in RR-MCF-7 than control group (Figure 5).
Figure 4: Comparison of Bcl-2 level in irradiated sampleswith RR-MCF-7.
Figure 5: Comparison of Western blot band intensity.
4. DiscussionRadioresistance is a barrier in cancer treatment andaffects the recovery process of patients. A long termexposure of cells to ionizing radiation induces anadaptive response that results in enhanced tolerance tothe subsequent cytotoxicity of ionizing radiation.10Cancer initiating cells and cancer stem cells are themajor cause for the development of radioresistantcharacter.11 Fractionated radiation treatment is one ofthe well know method to develop radioresistance incancer cell line. There were many other strategies wereapplied to develop radioresistant cancer cell lines12, 6, 7.Fractionated radiation treatment has also reported tocause drug resistance in ovarian13 and ascites14 tumorcells. It can induce the expression of multi drug resistantgene and its protein.15 The present study focused onnew method to develop radioresistant character inbreast cancer cell line. The cells survived after the highdosage exposure may develop the characters ofradioresistance and collection of clones of such cellsfrom the clonogenic assay may give the population ofuniform cells with these characters. Radioresistant cellsare known for over expressing antiapoptotic proteinsuch as Bcl-2.16
5. ConclusionThe present study showed the overexpression of Bcl-2 inRR-MCF-7 cells, which shows a sign of resistancecharacter. However the radioresistant cells showedelevated LDH level when compared with non-irradiated
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group. Further studies may be needed to check themembrane integrity in irradiated cells. Similar findingswere highlighting in apoptosis process; percentages ofapoptotic cells in 4 Gy exposed RR-MCF-7 cells werecomparatively lesser than MCF-7 control group. Overexpression of the Bcl-2 is the major reason for theinhibition of apoptosis process.
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